Clinical Research Advantage (CRA) entered into a strategic agreement with Quintiles to increase clinical trial participation. The firms aim to emphasize safety, as well as improve study efficiencies and data quality in medical research. CRA offers a mechanism for medical professionals to conduct Phase II–IV clinical research trials by providing coordinating and regulatory support.

“Clinical Research Advantage impressed us with their high standards for quality, high patient enrollments, and exceptional study start-up abilities,” says Lindy Jones, svp, integrated site services, Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society.”

Previous articlemRNA Vaccines Protect Animals Against Influenza
Next articleActiviomics Inks Cell Signaling Research Agreement